BTG plc (LON:BTG)‘s stock had its “neutral” rating restated by investment analysts at JPMorgan Chase & Co. in a research note issued on Tuesday. They presently have a GBX 790 ($9.93) price target on the stock. JPMorgan Chase & Co.’s price target indicates a potential upside of 37.75% from the company’s previous close.
A number of other equities research analysts have also recently weighed in on BTG. Jefferies Group LLC reaffirmed a “buy” rating and set a GBX 860 ($10.81) price target on shares of BTG plc in a report on Thursday, January 5th. Panmure Gordon reaffirmed a “buy” rating and set a GBX 737 ($9.26) price target on shares of BTG plc in a report on Thursday, January 5th. Peel Hunt started coverage on BTG plc in a report on Wednesday, January 25th. They set a “hold” rating and a GBX 630 ($7.92) price target for the company. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 900 ($11.31) price target on shares of BTG plc in a report on Wednesday, January 25th. Finally, Deutsche Bank AG dropped their price target on BTG plc from GBX 800 ($10.05) to GBX 775 ($9.74) and set a “buy” rating for the company in a report on Thursday, January 26th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. BTG plc currently has an average rating of “Buy” and a consensus price target of GBX 765.25 ($9.62).
Shares of BTG plc (LON:BTG) opened at 572.50 on Tuesday. The stock’s 50 day moving average price is GBX 570.03 and its 200 day moving average price is GBX 602.21. BTG plc has a one year low of GBX 528.36 and a one year high of GBX 739.50. The stock’s market capitalization is GBX 2.20 billion.
TRADEMARK VIOLATION NOTICE: “BTG plc (BTG) Rating Reiterated by JPMorgan Chase & Co.” was first reported by Mideast Time and is the property of of Mideast Time. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.mideasttime.com/btg-plc-btg-rating-reiterated-by-jpmorgan-chase-co-2/1589906.html.
About BTG plc
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.